Frontiers in medicine · 2026
Increased severity and relapse rate in adult anti-nuclear matrix protein 2 antibody positive myositis patients with distal limb weakness: a retrospective study in China.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liang Lin, Li Shanshan, Wei Qilu, Chen Shuo, Gao Ruilong, Sun Chao, Zhu Jianyu, Duan Jianghui, Zhang Ling
Аннотация
PURPOSE: This study aimed to examine the clinical features and prognosis of patients with distal limb weakness in anti-nuclear matrix protein 2 antibody (anti-NXP2) positive myositis.
PATIENTS AND METHODS: This retrospective study included the medical records of patients with anti-NXP2 antibody and follow-up data. Clinical features and prognosis of patients with and without distal limb weakness were compared. The differences in groups and survival analysis were analyzed using SPSS.
RESULTS: Of 110 enrolled adult patients with anti-NXP2 positive myositis, 53 showed distal limb weakness. The frequency of distal limb weakness in patients with anti-NXP2 positive myositis was highest when compared with other dermatomyositis (DM) patients. In the patients with anti-NXP2 positive myositis, the mean onset age of distal limb weakness group was younger, when compared with those without distal limb weakness (38.40 ± 13.36 vs. 46.26 ± 15.02 years, p = 0.005). They exhibited higher disease activity and experienced higher frequencies of severe muscle weakness, subcutaneous edema, dysphagia, and abnormal ECG (all p < 0.05). In terms of treatment, 32.1% patients with distal limb weakness received glucocorticoid (GC) pulse, which was higher than those without distal limb weakness (7.0%, p = 0.001). There were 32 patients reporting relapse. The mean dose of GC (prednisone equivalent) at relapse was higher. Nine patients with distal limb weakness died during follow-up, with infection representing the leading cause of death. The survival rate was not different in patients with and without distal limb weakness.
CONCLUSION: Adult patients with anti-NXP2 positive myositis and distal limb weakness were younger at disease onset and exhibited increased disease activity, including a higher prevalence of multi-system involvement, as well as a higher incidence of relapse during follow-up.
PATIENTS AND METHODS: This retrospective study included the medical records of patients with anti-NXP2 antibody and follow-up data. Clinical features and prognosis of patients with and without distal limb weakness were compared. The differences in groups and survival analysis were analyzed using SPSS.
RESULTS: Of 110 enrolled adult patients with anti-NXP2 positive myositis, 53 showed distal limb weakness. The frequency of distal limb weakness in patients with anti-NXP2 positive myositis was highest when compared with other dermatomyositis (DM) patients. In the patients with anti-NXP2 positive myositis, the mean onset age of distal limb weakness group was younger, when compared with those without distal limb weakness (38.40 ± 13.36 vs. 46.26 ± 15.02 years, p = 0.005). They exhibited higher disease activity and experienced higher frequencies of severe muscle weakness, subcutaneous edema, dysphagia, and abnormal ECG (all p < 0.05). In terms of treatment, 32.1% patients with distal limb weakness received glucocorticoid (GC) pulse, which was higher than those without distal limb weakness (7.0%, p = 0.001). There were 32 patients reporting relapse. The mean dose of GC (prednisone equivalent) at relapse was higher. Nine patients with distal limb weakness died during follow-up, with infection representing the leading cause of death. The survival rate was not different in patients with and without distal limb weakness.
CONCLUSION: Adult patients with anti-NXP2 positive myositis and distal limb weakness were younger at disease onset and exhibited increased disease activity, including a higher prevalence of multi-system involvement, as well as a higher incidence of relapse during follow-up.